Company Overview and News
(Reuters) - Ides Capital, one of only two U.S. activist hedge funds run by a woman, was partly behind the appointment of a female independent director this week at U.S. industrial technology company AstroNova Inc, people familiar with the matter said on Wednesday.
A recent intelligence study by Transparency Market Research (TMR) has detected that the global allergy treatment market is dominated by ALK-Abelló A/S when it comes to immunotherapy, whereas GlaxoSmithKline plc. Holds the pole position in the market in terms of anti-allergic drugs. The positions hold true for the base year of this report, the end of the year 2016. The stronghold of these two companies over the global allergy treatment market is primarily attributed to their impressive product portfolio and widespread geographical presence.
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announced today that it completed enrollment in a pivotal Phase III clinical study to evaluate the safety and efficacy of its investigational sublingual immunotherapy tablet STG320 for the treatment of house dust mite (HDM) induced allergic rhinitis. The study recruited over 1,600 patients from 13 countries with 231 participating investigative sites, and is the largest study of its kind.
Report Details The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.3% from 2016-2027. The market is estimated at $11.9bn in 2016 and $13.9bn in 2021. Read the full report: http://www.reportlinker.com/p04974738/Global-Allergic-Rhinitis-Drugs-Market.html How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
Stallergenes Greer plc (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, announced today the appointment of Matthias Vogt as its Chief Financial Officer (CFO), effective as of October 1st. Matthias Vogt will lead Stallergenes Greer’s global Finance function. He will report directly to Fereydoun Firouz, Chairman and CEO of Stallergenes Greer, and will be based in London.
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announces that following the completion of a formal audit tender process, conducted in accordance with the relevant requirements and led by the Company's Audit Committee, the Board has approved the appointment of EY LLP as the Company's auditor for the financial year commencing 1 January 2017.
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announced positive results from a real-world evidence (RWE) study on the long-term effectiveness of grass pollen sublingual immunotherapy (SLIT) treatment vs. symptomatic drugs. This is the first study that is based on eight years’ worth of data to demonstrate the long-term effectiveness of SLIT tablets including Stallergenes Greer’s tablet ORALAIR®.
Stallergenes Greer Plc (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announces that all resolutions proposed by the Board of Directors at the company’s Annual General Meeting (AGM) were duly passed today. All resolutions were set out in the Notice of Meeting posted to shareholders on 3 May 2017.
The shareholders of Stallergenes Greer plc (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, are hereby informed that they are invited to attend the Annual General Meeting at Palais Brongniart, 28 Place de la Bourse, 75002 Paris, France, on 8 June 2017 at 2:00p.m. (CET).
Stallergenes Greer (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, today announces the publication of its 2016 Annual Report.
Stallergenes Greer (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that its commercialization partner in Japan, Shionogi & Co. Ltd. (Shionogi), submitted its New Drug Application (NDA) for ACTAIR®, an investigational allergy immunotherapy sublingual tablet for the treatment of house dust mite (HDM) induced allergic rhinitis in children 5 to 11 years old.
Stallergenes Greer plc (the “Company”) (Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, has today sent a notice to shareholders, the full table of which is set out below.
NEW YORK, Jan. 31, 2017 /PRNewswire/ -- The allergy diagnostics market is expected to reach USD 5.34 billion by 2021 from USD 2.98 billion in 2016, at a CAGR of 12.4%. The global allergy diagnostics market is segmented based on product, allergen, test, end user, and region. The assay kits segment is expected to register the highest growth rate in the allergy diagnostics market, by product, during the forecast period.
Stallergenes Greer plc (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that Peter Bühler has resigned as Chief Financial Officer. His last day will be April 28, 2017.
Stallergenes Greer (the “Company”) (Euronext Paris: STAGR) (Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced positive topline results for a Phase 3 clinical study of its sublingual immunotherapy tablet (STG320) for the treatment of house dust mite (HDM) induced allergic rhinitis in the pediatric population, which was conducted in Japan by its partner Shionogi & Co.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...